DAX22.968 -2,3%Est505.625 -2,0%MSCI World4.343 -0,1%Top 10 Crypto9,4000 -2,1%Nas22.152 -1,5%Bitcoin61.240 -1,5%Euro1,1477 +0,1%Öl114,1 +4,1%Gold4.684 -3,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Siemens Energy ENER6Y SAP 716460 NVIDIA 918422 DroneShield A2DMAA Vonovia A1ML7J Lufthansa 823212 Deutsche Telekom 555750 Commerzbank CBK100 Allianz 840400 Volkswagen (VW) vz. 766403 Deutsche Bank 514000 Shell (ex Royal Dutch Shell) A3C99G NEL ASA A0B733 RENK RENK73
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
EZB im Fokus: DAX tiefrot -- Asiens Börsen letztlich schwächer -- Micron-Zahlen: Gewinn vervielfacht -- Fed-Zinsen bleiben stabil -- Rüstungsaktien, Siemens Energy, Tesla, NVIDIA, BYD im Fokus
Top News
BP-Aktie steigt: Konzern treibt Schuldenabbau mit Raffinerie-Verkauf voran BP-Aktie steigt: Konzern treibt Schuldenabbau mit Raffinerie-Verkauf voran
HELLA-Aktie leichter: Nettoergebnis stark rückläufig - Ausschüttung sinkt drastisch HELLA-Aktie leichter: Nettoergebnis stark rückläufig - Ausschüttung sinkt drastisch
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Novartis Aktie

Kaufen
Verkaufen
Novartis Aktien-Sparplan
128,50 EUR -2,00 EUR -1,53 %
STU
147,84 USD -7,04 USD -4,55 %
nachbörslich
BTT
finanzen.net zero
Novartis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone
KGV19,02Div. Rendite2,23%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN907122

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS66987V1098

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNVS

Novartis Aktien News

DatumMeistgelesen
Dow JonesPress Release: Novartis delivers 12% sales and -5-
Dow JonesPress Release: Novartis delivers 12% sales and -3-
Dow JonesPress Release: Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc(1)). Executes Sandoz spin-off, achieves imp...
GlobeNewswireNovartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane settin
Dow JonesPress Release: Novartis Pluvicto(TM) shows -2-
Dow JonesPress Release: Novartis Pluvicto(TM) shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic ...
GlobeNewswireNovartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
Dow JonesPress Release: Novartis Kisqali(R) NATALEE -2-
Dow JonesPress Release: Novartis Kisqali(R) NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast ...
GlobeNewswireNovartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer
Dow JonesPress Release: Novartis to present new oncology -2-
Dow JonesPress Release: Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer
GlobeNewswireNovartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company
GlobeNewswireNovartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
Dow JonesPress Release: Novartis investigational iptacopan -2-
Dow JonesPress Release: Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reducti...
Dow JonesPress Release: Novartis completes divestment of 'front of eye' ophthalmology assets
GlobeNewswireNovartis completes divestment of ‘front of eye’ ophthalmology assets
GlobeNewswireSandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
Dow JonesPress Release: Novartis: Sandoz receives European Commission approval for Tyruko(R) (natalizumab), first and only biosimilar for multiple sclerosis in Europe
GlobeNewswireNovartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (
Dow JonesPress Release: Novartis radioligand therapy -2-
Dow JonesPress Release: Novartis radioligand therapy Lutathera(R) demonstrated statistically significant and clinically meaningful progression-free survival in first ...
GlobeNewswireNovartis confirms Sandoz Spin-off for October 4, 2023
Dow JonesPress Release: Novartis confirms Sandoz Spin-off for October 4, 2023
GlobeNewswireSandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
Dow JonesPress Release: Novartis: Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
Dow JonesPress Release: Novartis shareholders approve the proposed 100% Spin-off of Sandoz
GlobeNewswireNovartis shareholders approve the proposed 100% Spin-off of Sandoz
PR NewswireNovartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization
GlobeNewswireSandoz announces exclusive deal to commercialize biosimilar ustekinumab, further reinforcing growing pipeline and immunology patient offering
Dow JonesPress Release: Novartis: Sandoz announces exclusive deal to commercialize biosimilar ustekinumab, further reinforcing growing pipeline and immunology patient...
GlobeNewswireNovartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Com
GlobeNewswireSandoz publishes supplement to Listing Prospectus including Sandoz H1 2023 financial statements
GlobeNewswireNovartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years
Dow JonesPress Release: Novartis presents new long-term -2-
Dow JonesPress Release: Novartis presents new long-term Leqvio(R) (inclisiran) data demonstrating consistent efficacy and safety beyond six years
GlobeNewswireSandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio
Dow JonesPress Release: Novartis: Sandoz completes acquisition of leading antifungal agent Mycamine(R) from Astellas, reinforcing leading global anti-infectives portf...
GlobeNewswireSandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis

Novartis News

Novartis News: auf dieser Seite finden Sie alle Novartis News und Nachrichten zur Novartis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novartis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novartis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.